Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome

Biaoru Li, Jie Yang, Ming Tao, Jaya Nayini, Erzsebet Horvath, Harpareet Chopra, Peterm Meyer, Paramesaran Venugopal, Harvey D. Preisler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)777-789
Number of pages13
JournalLeukemia Research
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2000

Fingerprint

Acute Myeloid Leukemia
Amifostine
Bone Marrow
Telomerase
Leukemia
Treatment Failure
Interleukin-6
Drug Therapy

Keywords

  • AML
  • Amifostine
  • Cytokines
  • Remission induction

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome. / Li, Biaoru; Yang, Jie; Tao, Ming; Nayini, Jaya; Horvath, Erzsebet; Chopra, Harpareet; Meyer, Peterm; Venugopal, Paramesaran; Preisler, Harvey D.

In: Leukemia Research, Vol. 24, No. 9, 01.09.2000, p. 777-789.

Research output: Contribution to journalArticle

Li, B, Yang, J, Tao, M, Nayini, J, Horvath, E, Chopra, H, Meyer, P, Venugopal, P & Preisler, HD 2000, 'Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome', Leukemia Research, vol. 24, no. 9, pp. 777-789. https://doi.org/10.1016/S0145-2126(00)00035-7
Li, Biaoru ; Yang, Jie ; Tao, Ming ; Nayini, Jaya ; Horvath, Erzsebet ; Chopra, Harpareet ; Meyer, Peterm ; Venugopal, Paramesaran ; Preisler, Harvey D. / Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome. In: Leukemia Research. 2000 ; Vol. 24, No. 9. pp. 777-789.
@article{3367da7679ed41a292138a03ba772a0c,
title = "Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome",
abstract = "Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.",
keywords = "AML, Amifostine, Cytokines, Remission induction",
author = "Biaoru Li and Jie Yang and Ming Tao and Jaya Nayini and Erzsebet Horvath and Harpareet Chopra and Peterm Meyer and Paramesaran Venugopal and Preisler, {Harvey D.}",
year = "2000",
month = "9",
day = "1",
doi = "10.1016/S0145-2126(00)00035-7",
language = "English (US)",
volume = "24",
pages = "777--789",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome

AU - Li, Biaoru

AU - Yang, Jie

AU - Tao, Ming

AU - Nayini, Jaya

AU - Horvath, Erzsebet

AU - Chopra, Harpareet

AU - Meyer, Peterm

AU - Venugopal, Paramesaran

AU - Preisler, Harvey D.

PY - 2000/9/1

Y1 - 2000/9/1

N2 - Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.

AB - Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.

KW - AML

KW - Amifostine

KW - Cytokines

KW - Remission induction

UR - http://www.scopus.com/inward/record.url?scp=0034284015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034284015&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(00)00035-7

DO - 10.1016/S0145-2126(00)00035-7

M3 - Article

C2 - 10978783

AN - SCOPUS:0034284015

VL - 24

SP - 777

EP - 789

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -